GlassScriptPhysician profile
Mae Sheikh Ali
NPI 1164405122
$750,781.12
in general payments reported to CMS, 2019-2025
52 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $208K · 2020: $82K · 2021: $111K · 2022: $198K · 2023: $84K · 2024: $32K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $23K · Consulting Fee: $16K · Food and Beverage: $7,051 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,950 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,472.50 |
| Travel and Lodging | $23,474.06 |
| Consulting Fee | $16,000.00 |
| Food and Beverage | $7,050.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,950.00 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301,246.44 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $144,115.56 | 2019-2023 | Mounjaro, Jardiance, Baqsimi |
| Amgen INC. | $102,685.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $90,878.72 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $25,937.74 | 2019-2024 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $19,169.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $16,045.25 | 2019-2020 | |
| Eli Lilly and Company | $13,992.22 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $10,926.30 | 2019-2020 | |
| Ibsa Pharma INC. | $10,537.23 | 2020-2024 | Tirosint, Tirosint, Licart |
| Radius Health, INC. | $3,891.76 | 2019-2022 | |
| Abbvie INC. | $1,956.89 | 2019-2023 | Synthroid |
| Tosoh Bioscience, INC. | $1,566.00 | 2019 | |
| Valeritas, INC. | $1,308.50 | 2019 | |
| Neuronetics, INC. | $1,104.37 | 2025 | Neurostar Tms Therapy System |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $943.33 | 2020-2025 | Recorlev |
| Insulet Corporation | $898.03 | 2019-2025 | Omnipod |
| Zealand Pharma US, INC. | $649.49 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.22 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $390.63 | 2019-2023 | |
| Horizon Therapeutics Plc | $291.83 | 2021-2023 | Tepezza |
| Dexcom, INC. | $229.41 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $221.11 | 2021-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $158.72 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $129.05 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $120.35 | 2019 | |
| Madrigal Pharmaceuticals | $114.01 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $105.96 | 2019-2023 | |
| Corcept Therapeutics | $94.50 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $74.29 | 2023-2025 | Myrbetriq, Veozah |
| Bard Peripheral Vascular, INC. | $57.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.06 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $50.83 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $46.49 | 2021-2022 | |
| Boston Scientific Corporation | $37.25 | 2021-2024 | |
| Shire North American Group INC | $36.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.87 | 2019 | |
| Senseonics, Incorporated | $35.00 | 2019 | |
| Vivus LLC | $32.01 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $28.00 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $26.17 | 2025 | Imcivree |
| Sequel Med Tech, LLC | $25.55 | 2025 | Twiist |
| Medtronic Minimed, INC. | $24.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.81 | 2023 | Strensiq |
| Ucb, INC. | $22.90 | 2019 | |
| Kyowa Kirin, INC. | $20.55 | 2023 | Crysvita |
| Beta Bionics, INC. | $19.02 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Grt US Holding, INC. | $15.05 | 2021 | |
| Endo Pharmaceuticals INC. | $13.21 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,546.72 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mae Sheikh Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.